

## ***Track record – Services – Health economics***

**The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.** Setiawan D, Luttjeboer J, Westra TA, Wilschut JC, Suwantika AA, Daemen T, Atthobari J, Wilffert B, Postma MJ. *Expert Rev Vaccines*. 2014 Dec 6:1-16. [Epub ahead of print]

**Cost-effectiveness of hepatitis A vaccination in Indonesia.** Suwantika AA, Beutels P, Postma MJ. *Hum Vaccin Immunother*. 2014;10(8):2342-9. doi: 10.4161/hv.29353.

**Cost-effectiveness of vaccination against herpes zoster.** de Boer PT, Wilschut JC, Postma MJ. *Hum Vaccin Immunother*. 2014 Jul;10(7):2048-61. doi: 10.4161/hv.28670.

**A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.** Vemer P, Postma MJ. *Hum Vaccin Immunother*. 2014 Jul;10(7):1841-9. doi: 10.4161/hv.29008.

**[Optimizing pharmacotherapy in patients with COPD by community-pharmacists: a cost-effectiveness analysis].** van Boven JF, Tommelein E, Boussey K, Mehuys E, Vegter S, Brusselle GG, Rutten-van Mülken MP, Postma MJ. *J Pharm Belg*. 2014 Sep;(3):15-6. French. No abstract available.

**Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.** Stevanović J, Pompen M, Le HH, Rozenbaum MH, Tieleman RG, Postma MJ. *PLoS One*. 2014 Aug 5;9(8):e103974. doi: 10.1371/journal.pone.0103974. eCollection 2014.

**A few years later: Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.** Vemer P, Postma MJ. *Hum Vaccin Immunother*. 2014 May 8;10(8). [Epub ahead of print]

**Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands.** de Vries FM, Denig P, Visser ST, Hak E, Postma MJ. *Value Health*. 2014 Mar;17(2):223-30. doi: 10.1016/j.jval.2013.12.010.

**Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.** Stevanović J, O'Prinsen AC, Verheggen BG, Schuiling-Veninga N, Postma MJ, Pechlivanoglou P. *Clin Ther*. 2014 Mar 1;36(3):368-84.e5. doi: 10.1016/j.clinthera.2014.01.008. Epub 2014 Feb 15.

**Budget constraint and vaccine dosing: a mathematical modelling exercise.** Standaert BA, Curran D, Postma MJ. *Cost Eff Resour Alloc*. 2014 Jan 22;12(1):3. doi: 10.1186/1478-7547-12-3.

**Economic evaluation of ropinirole prolonged release for treatment of Parkinson's disease in the Netherlands.** van Boven JF, Novak A, Driessen MT, Boersma C, Boomsma MM, Postma MJ. *Drugs Aging*. 2014 Mar;31(3):193-201. doi: 10.1007/s40266-013-0150-4.

**Costs and benefits of individuals conceived after IVF: a net tax evaluation in The Netherlands.** Moolenaar LM, Connolly M, Huisman B, Postma MJ, Hompes PG, van der Veen F, Mol BW. *Reprod Biomed Online*. 2014 Feb;28(2):239-45. doi: 10.1016/j.rbmo.2013.10.002. Epub 2013 Oct 10.

**Effect of breastfeeding promotion interventions on cost-effectiveness of rotavirus immunization in Indonesia.** Suwantika AA, Postma MJ. *BMC Public Health*. 2013 Dec 1;13:1106. doi: 10.1186/1471-2458-13-1106.

**Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.** Mihajlović J, Pechlivanoglou P, Sabo A, Tomić Z, Postma MJ. *Clin Ther*. 2013 Dec;35(12):1909-22. doi: 10.1016/j.clinthera.2013.10.004. Epub 2013 Nov 13.

**Economic impact of childhood/adolescent ADHD in a European setting: the Netherlands as a reference case.** Le HH, Hodgkins P, Postma MJ, Kahle J, Sikirica V, Setyawan J, Erder MH, Doshi JA. *Eur Child Adolesc Psychiatry*. 2014 Jul;23(7):587-98. doi: 10.1007/s00787-013-0477-8. Epub 2013 Oct 29.

**RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.** Meijboom MJ, Pouwels KB, Luytjes W, Postma MJ, Hak E. *Vaccine*. 2013 Dec 16;31(52):6254-60. doi: 10.1016/j.vaccine.2013.10.023. Epub 2013 Oct 19.

**Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.** Connolly MP, Kuyvenhoven JP, Postma MJ, Nielsen SK. *J Crohns Colitis*. 2014 May 1;8(5):357-62. doi: 10.1016/j.crohns.2013.09.015. Epub 2013 Oct 2.

**Treatment sequencing survival model for patients with multiple myeloma ineligible for stem cell transplantation (SCT).** Heeg B, Van Agthoven M, van Beurden-Tan C, Liwing J, Mellqvist U, Plesner T, Logman F, Aschan J, Einsele H, Treur M, Barendse M, Richardson PG, Palumbo A, Nahi H, Sonneveld P. *Value in health* 2014

**Sexually transmitted infections screening at HIV treatment centers for MSM can be cost-effective.** Vriend HJ, Lugner AK, Xiridou M, Schim van der Loeff MF, Prins M, de Vries HJ, Geerlings SE, Prins JM, Rijnders BJ, van Veen MG, Fennema JS, Postma MJ, van der Sande MA. *AIDS*. 2013 Sep 10;27(14):2281-90. doi: 10.1097/QAD.0b013e32836281ee.

**Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation.** Kotsopoulos N, Connolly MP, Postma MJ, Hutubessy RC. *Vaccine*. 2013 Nov 4;31(46):5430-4. doi: 10.1016/j.vaccine.2013.09.002. Epub 2013 Sep 18.

**Modelling the impact of chlamydia screening on the transmission of HIV among men who have sex with men.** Xiridou M, Vriend HJ, Lugner AK, Wallinga J, Fennema JS, Prins JM, Geerlings SE, Rijnders BJ, Prins M, de Vries HJ, Postma MJ, van Veen MG, Schim van der Loeff MF, van der Sande MA. *BMC Infect Dis*. 2013 Sep 18;13:436. doi: 10.1186/1471-2334-13-436.

**Is adding HCV screening to the antenatal national screening program in Amsterdam, the Netherlands, cost-effective?** Urbanus AT, van Keep M, Matser AA, Rozenbaum MH, Weegink CJ, van den Hoek A, Prins M, Postma MJ. *PLoS One*. 2013 Aug 12;8(8):e70319. doi: 10.1371/journal.pone.0070319. eCollection 2013.

**COPD in the working age population: the economic impact on both patients and government.** van Boven JF, Vegter S, van der Molen T, Postma MJ. *COPD*. 2013 Dec;10(6):629-39. doi: 10.3109/15412555.2013.813446. Epub 2013 Jul 11.

**Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.** Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ. *Vaccine*. 2013 Aug 20;31(37):3922-7. doi: 10.1016/j.vaccine.2013.06.044. Epub 2013 Jun 24.

**Meningococcal serogroup A, C, W<sub>135</sub> and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.** Hepkema H, Pouwels KB, van der Ende A, Westra TA, Postma MJ. *PLoS One*. 2013 May 31;8(5):e65036. doi: 10.1371/journal.pone.0065036. Print 2013.

**Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account.** Suwantika AA, Tu HA, Postma MJ. *Vaccine*. 2013 Jul 11;31(32):3300-7. doi: 10.1016/j.vaccine.2013.04.055. Epub 2013 May 21.

**The fiscal consequences of ADHD in Germany: a quantitative analysis based on differences in educational attainment and lifetime earnings.** Kotsopoulos N, Connolly MP, Sobanski E, Postma MJ. *J Ment Health Policy Econ*. 2013 Mar;16(1):27-33.

**Economic analysis of pandemic influenza mitigation strategies for five pandemic severity categories.** Kelso JK, Halder N, Postma MJ, Milne GJ. *BMC Public Health*. 2013 Mar 8;13:211. doi: 10.1186/1471-2458-13-211.

**Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.** Westra TA, Stirbu-Wagner I, Dorsman S, Tutuhaturnewa ED, de Vrij EL, Nijman HW, Daemen T, Wilschut JC, Postma MJ. *BMC Infect Dis*. 2013 Feb 7;13:75. doi: 10.1186/1471-2334-13-75.

**Economics of vaccines revisited.** Postma MJ, Standaert BA. *Hum Vaccin Immunother*. 2013 May;9(5):1139-41. doi: 10.4161/hv.23447. Epub 2013 Jan 30.

**An update of "Cost-effectiveness of rotavirus vaccination in the Netherlands: the results of a Consensus Rotavirus Vaccine model".** Tu HA, Rozenbaum MH, de Boer PT, Noort AC, Postma MJ. *BMC Infect Dis*. 2013 Jan 30;13:54. doi: 10.1186/1471-2334-13-54.

**Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands.** de Boer PT, Pouwels KB, Cox JM, Hak E, Wilschut JC, Postma MJ. *Vaccine*. 2013 Feb 18;31(9):1276-83. doi: 10.1016/j.vaccine.2012.12.067. Epub 2013 Jan 8.

**Accumulating evidence for the case of differential discounting.** Postma MJ, Parouty M, Westra TA. *Expert Rev Clin Pharmacol*. 2013 Jan;6(1):1-3. doi: 10.1586/ecp.12.73. No abstract available.

**Dynamic models for health economic assessments of pertussis vaccines: what goes around comes around....** Rozenbaum MH, De Cao E, Westra TA, Postma MJ. *Expert Rev Vaccines*. 2012 Dec;11(12):1415-28. doi: 10.1586/erv.12.130. Review.

**Response on "RE: Cost-effectiveness of pertussis booster vaccination in the Netherlands".** Rozenbaum MH, Postma MJ. *Vaccine*. 2013 Apr 12;31(16):2024. doi: 10.1016/j.vaccine.2012.11.082. Epub 2012 Dec 11. No abstract available.

**A Model to Evaluate the Immunogenicity Costs of Tumour Necrosis Factor-Alpha Inhibitors in Patients with Rheumatoid Arthritis.** Heeg B, Majer I, Stephens J, Tarallo M. *Value in Health*, Vol. 16, Issue 7, A563. November, 2013

**Cost-effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions.** Farkouh RA, Klok RM, Postma MJ, Roberts CS, Strutton DR. *Expert Rev Vaccines*. 2012 Oct;11(10):1235-47. doi: 10.1586/erv.12.99. Epub 2012 Nov 21. Review.

**Dynamic modeling for pandemic influenza.** Postma MJ. *Expert Rev Vaccines*. 2012 May;11(5):543-6. doi: 10.1586/erv.12.30.

**Cost effectiveness of vaccination against pandemic influenza in European countries: mathematical modelling analysis.** Lugnér AK, van Boven M, de Vries R, Postma MJ, Wallinga J. *BMJ*. 2012 Jul 12;345:e4445. doi: 10.1136/bmj.e4445.

**Cost-effectiveness of pertussis booster vaccination in the Netherlands.** Rozenbaum MH, De Cao E, Postma MJ. *Vaccine*. 2012 Nov 26;30(50):7327-31. doi: 10.1016/j.vaccine.2012.06.026. Epub 2012 Jun 27.

**On discounting of health gains from human papillomavirus vaccination: effects of different approaches.** Westra TA, Parouty M, Brouwer WB, Beutels PH, Rogoza RM, Rozenbaum MH, Daemen T, Wilschut JC, Boersma C, Postma MJ. *Value Health*. 2012 May;15(3):562-7. doi: 10.1016/j.jval.2012.01.005. Epub 2012 Mar 29.

**Cost-effectiveness of potential infant vaccination against respiratory syncytial virus infection in The Netherlands.** Meijboom MJ, Rozenbaum MH, Benedictus A, Luytjes W, Kneyber MC, Wilschut JC, Hak E, Postma MJ. *Vaccine*. 2012 Jun 29;30(31):4691-700. doi: 10.1016/j.vaccine.2012.04.072. Epub 2012 May 2.

**Economic evaluation of anti-epileptic drug therapies with specific focus on teratogenic outcomes.** Jentink J, Boersma C, de Jong-van den Berg LT, Postma MJ. *J Med Econ*. 2012;15(5):862-8. doi: 10.3111/13696998.2012.684366. Epub 2012 May 3.

**Practical implications of differential discounting of costs and health effects in cost-effectiveness analysis.** Westra TA, Parouty MB, Wilschut JC, Boersma C, Postma MJ. *Value Health*. 2011 Dec;14(8):1173-4; author reply 1174-5. doi: 10.1016/j.jval.2011.07.013. Epub 2011 Nov 12. No abstract available.

**Flexibility of Markov modeling for clinical pharmacoeconomics: illustration for cost-effectiveness in early Parkinson's disease.** Postma MJ, Boersma C. *Expert Rev Clin Pharmacol*. 2012 Jan;5(1):1-4. doi: 10.1586/ecp.11.69. No abstract available.

**Health economics of rotavirus immunization in Vietnam: potentials for favorable cost-effectiveness in developing countries.** Tu HA, Rozenbaum MH, Coyte PC, Li SC, Woerdenbag HJ, Postma MJ. *Vaccine*. 2012 Feb 14;30(8):1521-8. doi: 10.1016/j.vaccine.2011.11.052. Epub 2011 Nov 23.

**Economic evaluation of dabigatran etexilate for the primary prevention of venous thromboembolic events following major orthopedic surgery in the Netherlands.** Postma MJ, Kappelhoff BS, van Hulst M, Brouwers JR. *J Med Econ*. 2012;15(5):878-86. doi: 10.3111/13696998.2012.691144. Epub 2012 Jun 7.

**The cost-effectiveness of paliperidone extended release in Spain.** Treur M, Baca E, Bobes J, Cañas F, Salvador L, Gonzalez B, Heeg B. *Journal of Medical Economics* 2012;15 Suppl 1:26-34

**Modelling the impact of extended vaccination strategies on the epidemiology of pertussis.** Rozenbaum MH, De Vries R, LE HH, Postma MJ. *Epidemiol Infect*. 2012 Aug;140(8):1503-14. doi: 10.1017/S0950268811002354. Epub 2011 Nov 24.

**The long-term fiscal impact of funding cuts to Danish public fertility clinics.** Connolly MP, Postma MJ, Crespi S, Andersen AN, Ziebe S. *Reprod Biomed Online*. 2011 Dec;23(7):830-7. doi: 10.1016/j.rbmo.2011.09.011. Epub 2011 Sep 29.

**Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis.** Vegter S, Tolley K, Keith MS, Postma MJ. *Value Health*. 2011 Sep-Oct;14(6):852-8. doi: 10.1016/j.jval.2011.05.005. Epub 2011 Jun 23.

**Health technology assessments in personalized medicine: illustrations for cost-effectiveness analysis.** Postma MJ, Boersma C, Vandijck D, Vegter S, Le HH, Annemans L. *Expert Rev Pharmacoecon Outcomes Res.* 2011 Aug;11(4):367-9. doi: 10.1586/erp.11.50. No abstract available.

**Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model.** Rozenbaum MH, Mangen MJ, Giaquinto C, Wilschut JC, Hak E, Postma MJ; Consensus Group on Dutch Rotavirus Vaccination (CoRoVa-Group). *BMC Public Health.* 2011 Jun 10;11:462. doi: 10.1186/1471-2458-11-462.

**Cost benefit and cost effectiveness of antifungal prophylaxis in immunocompromised patients treated for haematological malignancies: reviewing the available evidence.** Pechlivanoglou P, De Vries R, Daenen SM, Postma MJ. *Pharmacoeconomics.* 2011 Sep;29(9):737-51. doi: 10.2165/11588370-000000000-00000. Review.

**Preventable hospital admissions related to medication (HARM): cost analysis of the HARM study.** Leendertse AJ, Van Den Bemt PM, Poolman JB, Stoker LJ, Egberts AC, Postma MJ. *Value Health.* 2011 Jan;14(1):34-40. doi: 10.1016/j.jval.2010.10.024.

**Until which age should women be vaccinated against HPV infection? Recommendation based on cost-effectiveness analyses.** Westra TA, Rozenbaum MH, Rogoza RM, Nijman HW, Daemen T, Postma MJ, Wilschut JC. *J Infect Dis.* 2011 Aug 1;204(3):377-84. doi: 10.1093/infdis/jir281.

**Ticagrelor for the Treatment of Acute Coronary Syndromes (ACS): A Dutch Analysis Based on the Plato Trial.** Thurston S, Heeg B, Hofsté C. *PCV87 Value in Health* 01/2011; 14(7)

**Cost-Effectiveness of Atazanavir/R Compared to Darunavir/R in Germany.** Thuresson P, Verheggen B, Heeg B, Kaspar I, Erhardt W, Lescauwet B. *PIN82 Value in Health* 01/2011; 14(7).

**Modeling the Long Term Clinical Outcomes and Health Care Cost Impact of Initiating Treatment with Atazanavir/R Compared with Darunavir/R, Lopinavir/R and Efavirenz for HIV1 Infected Treatment-Naïve Patients: Country Results for Italy, Spain, Portugal and UK.** Thuresson P. O., Verheggen B., Heeg B., Aldir I., Carrasco J., Didoni G., Mesa O. A., Lescauwet B. *PIN73 Value in Health* 01/2011; 14(7)

**Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.** Thuresson P, Heeg B, Lescauwet B, Sennfält K, Alaeus A, Neubauer A. *Scandinavian Journal of Infectious Diseases* 01/2011; 43(4):304-1

**Optimal Treatment Sequencing In Multiple Myeloma: An Exploratory Modeling Approach.** Heeg B, Van Agthoven M, Liwing J, Mellqvist U, Plesner T, Logman F, Aschan J, Einsele H, Treur M, Barendse M, Richardson PG, Palumbo A, Nahi H, Sonneveld P. in 53rd ASH Annual Meeting and Exposition. 2011.

**Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.** Postma MJ, Milne G, Nelson EA, Pyenson B, Basili M, Coker R, Oxford J, Garrison LP Jr; PI Group. *Expert Rev Anti Infect Ther.* 2010 Dec;8(12):1431-9. doi: 10.1586/eri.10.136. Review.

**Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.** de Vries R, Kretzschmar M, Schellekens JF, Versteegh FG, Westra TA, Roord JJ, Postma MJ. *PLoS One.* 2010 Oct 15;5(10):e13392. doi: 10.1371/journal.pone.0013392.

**Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged > or =65 years in the Netherlands.** Rozenbaum MH, Hak E, van der Werf TS, Postma MJ. *Clin Ther.* 2010 Aug;32(8):1517-32. doi: 10.1016/j.clinthera.2010.06.016.

**Cost-effectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands.** Westra TA, de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ. *Clin Ther.* 2010 Aug;32(8):1479-95. doi: 10.1016/j.clinthera.2010.07.017.

**Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines.** Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelen G, Rodenburg GD, Hak E, Postma MJ. *BMJ.* 2010 Jun 2;340:c2509. doi: 10.1136/bmj.c2509.

**Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar).** Rozenbaum MH, Hoek AJ, Hak E, Postma MJ. *Vaccine*. 2010 Mar 11;28(12):2367-9. doi: 10.1016/j.vaccine.2010.01.005. Epub 2010 Jan 17.

**Health economics of blood transfusion safety—focus on sub-Saharan Africa.** van Hulst M, Smit Sibinga CT, Postma MJ. *Biologicals*. 2010 Jan;38(1):53-8. doi: 10.1016/j.biologicals.2009.10.006. Epub 2009 Dec 21. Review.

**Mitigation of pandemic influenza: review of cost-effectiveness studies.** Lugnér AK, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2009 Dec;9(6):547-58. doi: 10.1586/erp.09.56. Review.

**[Efficiency of human papillomavirus vaccination—estimates based on Dutch cost effectiveness analyses].** Westra TA, Daemen T, Postma MJ, Wilschut JC. *Ned Tijdschr Geneeskd*. 2009;153:A356. Review. Dutch.

**Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review.** Postma MJ, de Vries R, Roord J. *Vaccine*. 2009 Dec 9;27(52):7242-3. doi: 10.1016/j.vaccine.2009.08.077. Epub 2009 Sep 8.

**Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.** Boersma C, Gansevoort RT, Pechlivanoglou P, Visser ST, van Toly FF, de Jong-van den Berg LT, de Jong PE, Postma MJ; Prevention of Renal and Vascular End Stage Disease Study Group. *Clin Ther*. 2010 Jun;32(6):1103-21. doi: 10.1016/j.clinthera.2010.06.013.

**Cost effectiveness of angiotensin receptor blocker monotherapy in patients with hypertension in the Netherlands: a comparative analysis using clinical trial and drug utilization data.** Boersma C, Voors AA, Visser ST, de Jong-van den Berg LT, Postma MJ. *Am J Cardiovasc Drugs*. 2010;10(1):49-54. doi: 10.2165/11319570-000000000-00000.

**. Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial.** Thurston S, Heeg B, de Charro F, van Hout B. *Current Medical Research and Opinion* 03/2010; 26(3):641-51.

**Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.** Logman F, Heeg B, Herlitz J, van Hout B. *Applied Health Economics and Health Policy* 01/2010; 8(4):251-65.

**Cost-effectiveness of atazanavir/r vs. Lopinavir/r in treatment naive hiv patients in Spain.** Thuresson P, Heeg B, Serrano O, Ramirez de Arellano. *PIN56 Value in Health* 10/2009; 12(7)

**Cost Effectiveness of Long-Acting Risperidone in Sweden.** Hensen M, Heeg B, Lothgren M, van Hout B. *Applied Health Economics and Health Policy* 01/2010; 8(5):327-341.

**Canadian cost-effectiveness analysis of long-acting risperidone versus oral atypical and conventional depot antipsychotics in patients with schizophrenia at high-risk of non-compliance: updated based on new clinical data.** Lam A, Heeg B. *Pmh55 Value in Health* 01/2010; 13(3).

**Discrete event simulation model in major depressive disorder: life-time health outcomes of adjunctive atypical antipsychotics.** Treur M, Pitchot W, Postema R, Loze JY, Heeg B, Drost P. *PMH11. Value in Health* 01/2010; 13(3)

**Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.** Logman JF, Heeg BM, Botteman MF, Kaura S, van Hout BA. *Ann Oncol*. 2010 Jul;21(7):1529-36. doi: 10.1093/annonc/mdp560. Epub 2009 Dec 2.

**Economics of assisted reproduction: access to fertility treatments and valuing live births in economic terms.** Connolly MP, Ledger W, Postma MJ. *Hum Fertil (Camb)*. 2010 Mar;13(1):13-8. doi: 10.3109/14647270903401747. Review.

**Cost-effectiveness analysis of Human Papillomavirus (HPV) vaccination in the Netherlands: recent publication reinforces favorable cost-effectiveness despite misleading conclusion.** Postma MJ. *Vaccine*. 2010 Jan 22;28(4):873-4. doi: 10.1016/j.vaccine.2009.10.109. Epub 2009 Nov 5. No abstract available.

**Web interface-supported transmission risk assessment and cost-effectiveness analysis of postdonation screening: a global model applied to Ghana, Thailand, and the Netherlands.** van Hulst M, Hubben GA, Sagoe KW, Promwong C, Permpikul P, Fongsatitkul L, Glynn DM, Sibinga CT, Postma MJ. *Transfusion*. 2009 Dec;49(12):2729-42. doi: 10.1111/j.1537-2995.2009.02351.x. Epub 2009 Aug 25.

**Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.** Lugner AK, Postma MJ. *Eur J Public Health*. 2009 Oct;19(5):516-20. doi: 10.1093/eurpub/ckp119. Epub 2009 Aug 19.

**The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus.** Postma MJ, de Zeeuw D. *Nephrol Dial Transplant*. 2009 Oct;24(10):2975-83. doi: 10.1093/ndt/gfp352. Epub 2009 Jul 15. Review. No abstract available.

**Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.** Rogoza RM, Westra TA, Ferko N, Tamminga JJ, Drummond MF, Daemen T, Wilschut JC, Postma MJ. *Vaccine*. 2009 Jul 30;27(35):4776-83. doi: 10.1016/j.vaccine.2009.05.085. Epub 2009 Jun 17.

**The dynamic field of pharmacoeconomics.** Postma MJ. *Expert Rev Clin Pharmacol*. 2009 Mar;2(2):125-7. doi: 10.1586/17512433.2.2.125.

**Cost-effectiveness of a potential future Helicobacter pylori vaccine in the Netherlands: the impact of varying the discount rate for health.** de Vries R, Klok RM, Brouwers JR, Postma MJ. *Vaccine*. 2009 Feb 5;27(6):846-52. doi: 10.1016/j.vaccine.2008.11.081. Epub 2008 Dec 11.

**Incremental cost effectiveness of proton pump inhibitors for the prevention of non-steroidal anti-inflammatory drug ulcers: a pharmacoeconomic analysis linked to a case-control study.** Vonkeman HE, Braakman-Jansen LM, Klok RM, Postma MJ, Brouwers JR, van de Laar MA. *Arthritis Res Ther*. 2008;10(6):R144. doi: 10.1186/ar2577. Epub 2008 Dec 16.

**Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism.** Vegter S, Perna A, Hiddema W, Ruggerenti P, Remuzzi G, Navis G, Postma MJ. *Pharmacogenet Genomics*. 2009 Sep;19(9):695-703. doi: 10.1097/FPC.0b013e3283307ca0.

**A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss.** Treur M, Heeg B, Möller HJ, Schmeding A, van Hout B. *BMC Health Services Research* 03/2009; 9:32

**Economic evaluation of zoledronic acid for the prevention of osteoporotic fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the UK.** Logman JF, Heeg B, Botteman MF, Kaura S, van Hout BA. *Annals of Oncology* 12/2009; 21(7):1529-36.

**Cost-effectiveness analysis of alpha-blocker and antimuscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder: application to the United Kingdom.** Verheggen BG, Lee R, Treur M, Heeg B, Botteman M, Mollon P, Trocio J, Bavendam T, Kaplan S. *PUK9. Value in Health* 05/2009; 12(3)

**Cost-effectiveness estimates for antenatal HIV testing in the Netherlands.** Rozenbaum MH, Verweel G, Folkerts DK, Dronkers F, van den Hoek JA, Hartwig NG, de Groot R, Postma MJ. *Int J STD AIDS*. 2008 Oct;19(10):668-75. doi: 10.1258/ijsa.2008.008077.

**Vancomycin vs teicoplanin in the treatment of Gram-positive infections: a pharmacoeconomic analysis in a Turkish University Hospital.** Sancar AA, Yegenoglu S, de Vries R, Postma MJ, Simsek N, Pechlivanoglou P, Unal S. *Pharm World Sci*. 2008 Dec;30(6):916-23. doi: 10.1007/s11096-008-9251-2. Epub 2008 Sep 21.

**HCV screening to enable early treatment of hepatitis C: a mathematical model to analyse costs and outcomes in two populations.** Tramarin A, Gennaro N, Compostella FA, Gallo C, Wendelaar Bonga LJ, Postma MJ. *Curr Pharm Des*. 2008;14(17):1655-60.

**Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model.** Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, Longini IM Jr. *Value Health*. 2009 Mar-Apr;12(2):226-33. doi: 10.1111/j.1524-4733.2008.00437.x. Epub 2008 Jul 30.

**Cost-effectiveness of HIV screening of blood donations in Accra (Ghana).** van Hulst M, Sagoe KW, Vermande JE, van der Schaaf IP, van der Tuuk Adriani WP, Torpey K, Ansah J, Mingle JA, Smit Sibinga CT, Postma MJ. *Value Health*. 2008 Sep-Oct;11(5):809-19. doi: 10.1111/j.1524-4733.2008.00337.x. Epub 2008 May 16.

**The societal burden of HIV/AIDS in Northern Italy: an analysis of costs and quality of life.** Hubben GA, Bishai D, Pechlivanoglou P, Cattelan AM, Grisetti R, Facchin C, Compostella FA, Bos JM, Postma MJ, Tramarin A. *AIDS Care*. 2008 Apr;20(4):449-55. doi: 10.1080/09540120701867107.

**Cost-utility of repeated screening for Chlamydia trachomatis.** de Vries R, van Bergen JE, de Jong-van den Berg LT, Postma MJ; PILOT-CT study group. *Value Health*. 2008 Mar-Apr;11(2):272-4. doi: 10.1111/j.1524-4733.2007.00225.x.

**Economic evaluation of folic acid food fortification in The Netherlands.** Jentink J, van de Vrie-Hoekstra NW, de Jong-van den Berg LT, Postma MJ. *Eur J Public Health*. 2008 Jun;18(3):270-4. doi: 10.1093/eurpub/ckm129. Epub 2008 Jan 31.

**Cost effectiveness of oseltamivir treatment of influenza: a critique of published methods and outcomes.** Postma MJ, Beardsworth P, Wilschut JC. *J Med Econ*. 2008;11(4):743-68. doi: 10.3111/13696990802505557. Review.

**Cost effectiveness of itraconazole in the prophylaxis of invasive fungal infections.** de Vries R, Daenen S, Tolley K, Glasmacher A, Prentice A, Howells S, Christopherson H, de Jong-van den Berg LT, Postma MJ. *Pharmacoeconomics*. 2008;26(1):75-90.

**Health economic methodology illustrated with recent work on Chlamydia screening: the concept of extended dominance.** Postma MJ, de Vries R, Welte R, Edmunds WJ. *Sex Transm Infect*. 2008 Apr;84(2):152-4. Epub 2007 Dec 12.

**Cost-effectiveness of tipranavir versus comparator protease inhibitor regimens in HIV infected patients previously exposed to antiretroviral therapy in the Netherlands.** Hubben GA, Bos JM, Veltman-Starkenburt CA, Stegmeijer S, Finnern HW, Kappelhoff BS, Simpson KN, Tramarin A, Postma MJ. *Cost Eff Resour Alloc*. 2007 Nov 22;5:15.

**Pharmacoeconomics of quetiapine for the management of acute mania in bipolar I disorder.** Klok RM, Al Hadithy AF, van Schayk NP, Antonisse AJ, Caro JJ, Brouwers JR, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2007 Oct;7(5):459-67. doi: 10.1586/14737167.7.5.459.

**Enhanced decision support for policy makers using a web interface to health-economic models—illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands.** Hubben GA, Bos JM, Glynn DM, van der Ende A, van Alphen L, Postma MJ. *Vaccine*. 2007 May 4;25(18):3669-78. Epub 2007 Feb 5.

**Cost-effectiveness analysis of caspofungin versus amphotericin b, voriconazole, and anidulafungin in the treatment of invasive candidiasis.** Verheggen BG, Heeg BM, Vos C, Van Hout BA. *Value in Health*, Vol. 11, Issue 6, A437

**Infectious disease economic evaluations in cost effectiveness analysis of reyataz<sup>®</sup> versus kaletra<sup>®</sup> in the treatment of naïve HIV patients in Italy.** Neubauer AS, Van Hout BA, Thuresson PO, Intorcchia M, Heeg B. *IN1 Value in health* 2008

**Inpatient and Outpatient Cost Model of Treating Gram+ Complicated Skin and Soft Tissue Infections (cSSTIs).** Tice A, Heeg B, Nathwani D, Stephens J. *Infectious Diseases Society of America 2008 Annual Meeting*; 10/2008

**Cost effectiveness analysis of reyataz<sup>®</sup> versus kaletra<sup>®</sup> in the treatment of naïve HIV patients in Italy.** Thuresson PO, Heeg B, Neubauer AS, Intorcchia M, Van Hout BA. *IN1 Value in Health* 01/2008; 11(6).

**The cost-effectiveness of atypicals in the UK.** Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, de Charro F, van Hout B. *Value in Health* 06/2008; 11(7):1007-21.

**Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modeling exercise.** Heeg B, Antunes J, Figueira M, Jara J, Marques Teixeira J, Palha A, Vaz Serra A, Buskens E, Caleo S, Gouveia-Pinto G, van Hout B. *Current Medical Research and Opinion* 03/2008; 24(2):349-58

**A pharmacoeconomic analysis of compliance gains on antipsychotic medications.** Damen J, Thuresson PO, Heeg B, Lothgren M. *Applied Health Economics and Health Policy* 02/2008; 6(4):189-97

**Modelling approaches: the case of schizophrenia.** Heeg B, Damen J, Buskens E, Caleo S, de Charro F, van Hout B. *Pharmacoeconomics* 02/2008; 26(8):633-48

**Cost-effectiveness and budget impact of long-acting risperidone in Portugal: a modelling exercise.** Pacheco Palha A, Heeg B, Antunes J, Figueira M, Jara J, Marques Teixeira J. *Current Medical Research and Opinion* 02/2008; 24(2):349-58.

**A pharmacoeconomic analysis of schizophrenic patients switching from branded to generic risperidone involving a possible compliance loss.** Treur M, Heeg B, Möller H, Schmeding A, van Hout BA. *PMH31 Value in Health* 01/2008; 11(3).

**Health-economic analysis of risperidone long-acting injectable compared to olanzapine and a conventional depot in Sweden and Finland.** Hensen M, Treur M, Heeg B, Lothgren M, Van Hout B. *98 –Schizophrenia Research – SCHIZOPHR RES*. 01/2008; 98:73-74

**The use of health economics to guide drug development decisions: Determining optimal values for an RSV-vaccine in a model-based scenario-analytic approach.** Bos JM, Rietveld E, Moll HA, Steyerberg EW, Luytjes W, Wilschut JC, de Groot R, Postma MJ. *Vaccine*. 2007 Sep 28;25(39-40):6922-9. Epub 2007 Jul 30.

**Estimation and prediction of the HIV-AIDS-epidemic under conditions of HAART using mixtures of incubation time distributions.** Heisterkamp SH, de Vries R, Sprenger HG, Hubben GA, Postma MJ. *Stat Med*. 2008 Mar 15;27(6):781-94.

**Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands.** Postma MJ, Novak A, Scheijbeler HW, Gyldmark M, van Genugten ML, Wilschut JC. *Pharmacoeconomics*. 2007;25(6):497-509.

**Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria.** Postma MJ, Boersma C, Gansevoort RT. *Nephrol Dial Transplant*. 2008 Apr;23(4):1103-6. Epub 2007 Jan 8. No abstract available.

**Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making.** Boersma C, Atthobari J, Gansevoort RT, de Jong-Van den Berg LT, de Jong PE, de Zeeuw D, Annemans LJ, Postma MJ. *Pharmacoeconomics*. 2006;24(6):523-35. Review.

**An economic assessment of losartan-based versus atenolol-based therapy in patients with hypertension and left-ventricular hypertrophy: results from the Losartan Intervention For Endpoint reduction (LIFE) study adapted to The Netherlands.** Boersma C, Carides GW, Atthobari J, Voors AA, Postma MJ. *Clin Ther*. 2007 May;29(5):963-71.

**Long-term clopidogrel therapy in patients receiving percutaneous coronary intervention.** Heeg B, Peters R, Botteman M, van Hout B. *Pharmacoeconomics* 02/2007; 25(9):769-82.

**Oral antiplatelet therapy in secondary prevention of cardiovascular events: an assessment from the payer's perspective.** Heeg B, Damen D, van Hout B. *Pharmacoeconomics* 02/2007; 25(12):1063-82.

**The cost effectiveness of paliperidone extended-release OROS in Sweden, Finland, Denmark and Norway.** Damen J, Heeg B, Lothgren M, van Hout BA. *PMH24 Value in Health* 01/2007; 10(6).

**Cost-effectiveness of zoledronic acid in the prevention of fractures in postmenopausal women with early breast cancer receiving aromatase inhibitor: Application to the United Kingdom.** Logman F, Heeg B, Botteman M, Marfatia A, van Hout B. 1146. *EJC Supplements* 09/2007; 5(4):156-156.

**Further evidence for favorable cost-effectiveness of elderly influenza vaccination.** Postma MJ, Baltussen RP, Palache AM, Wilschut JC. *Expert Rev Pharmacoecon Outcomes Res*. 2006 Apr;6(2):215-27. doi: 10.1586/14737167.6.2.215.

**Systematic screening for Chlamydia trachomatis: estimating cost-effectiveness using dynamic modeling and Dutch data.** de Vries R, van Bergen JE, de Jong-van den Berg LT, Postma MJ; PILOT-CT Study Group. *Value Health*. 2006 Jan-Feb;9(1):1-11.

**[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].** Heeg B, van Gestel A, van Hout B, Olsen J, Haghfelt T. *Ugeskrift for laeger* 09/2006; 168(35):2911-5

**Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.** Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U. *Transfus Med*. 2005 Oct;15(5):379-87.

**Discounting health effects in pharmacoeconomic evaluations: current controversies.** Bos JM, Postma MJ, Annemans L. *Pharmacoeconomics*. 2005;23(7):639-49.

**Need for differential discounting of costs and health effects in cost effectiveness analyses.** Brouwer WB, Niessen LW, Postma MJ, Rutten FF. *BMJ*. 2005 Aug 20;331(7514):446-8. No abstract available.

**Cost-effectiveness of leucocyte-depleted erythrocyte transfusion in cardiac valve surgery.** van Hulst M, Bilgin YM, van de Watering LM, de Vries R, van Oers MH, Brand A, Postma MJ. *Transfus Med*. 2005 Jun;15(3):209-17.

**Towards a healthier discount procedure.** Klock RM, Brouwer WB, Annemans LJ, Bos JM, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2005 Feb;5(1):59-63. doi: 10.1586/14737167.5.1.59.

**Valuing prevention through economic evaluation: some considerations regarding the choice of discount model for health effects with focus on infectious diseases.** Bos JM, Beutels P, Annemans L, Postma MJ. *Pharmacoeconomics*. 2004;22(18):1171-9. Review.



- Modelling the treated course of schizophrenia: development of a discrete event simulation model.** Heeg B, Buskens E, Knapp K, van Aalst G, Dries P, de Haan L, van Hout B. *PharmacoEconomics* 02/2005; 23 Suppl 1:17-33
- Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.** Laux G, Heeg B, van Hout B, Mehnert A. *PharmacoEconomics* 02/2005; 23 Suppl 1:49-61
- Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada.** Chue P, Heeg B, Buskens E, van Hout B. *PharmacoEconomics* 02/2005; 23 Suppl 1:62-74
- A discrete event simulation (des) model to describe schizophrenia.** Heeg B, Buskens E, Ingham M, Caleo S, Rabinowitz J, van Hout B. *PMH38. Value in Health* 01/2005; 8(6).
- Four quadrants of the cost-effectiveness plane: some considerations on the south-west quadrant.** Klok RM, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res.* 2004 Dec;4(6):599-601. doi: 10.1586/14737167.4.6.599. No abstract available.
- Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.** Welte R, van den Dobbelaars G, Bos JM, de Melker H, van Alphen L, Spanjaard L, Rümke HC, Postma MJ. *Vaccine.* 2004 Dec 9;23(4):470-9.
- Incremental cost-effectiveness of cyclooxygenase 2-selective versus nonselective nonsteroidal anti-inflammatory drugs in a cohort of coumarin users: a pharmaco-economic analysis linked to a case-control study.** Knijff-Dutmer EA, Postma MJ, van der Palen J, Brouwers JR, van de Laar MA. *Clin Ther.* 2004 Jul;26(7):1160-7.
- Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the Netherlands.** Jansman FG, Postma MJ, van Hartkamp D, Willemse PH, Brouwers JR. *Clin Ther.* 2004 Apr;26(4):579-89.
- Pharmacoeconomics of gastrointestinal drug utilisation prior and post *Helicobacter pylori* eradication.** Klok RM, van der Veen WJ, van der Werf GT, van den Berg PB, Brouwers JR, Postma MJ. *Helicobacter.* 2004 Feb;9(1):87-91.
- Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands).** Postma MJ, Bos JM, Beutels P, Schilthuis H, van den Hoek JA. *Vaccine.* 2004 May 7;22(15-16):1862-7.
- Cost-effectiveness of antenatal HIV-testing: reviewing its pharmaceutical and methodological aspects.** Postma MJ, Sagoe KW, Dronkers F, Sprenger HG, de Jong-van den Berg L, Beck EJ. *Expert Opin Pharmacother.* 2004 Mar;5(3):521-8. Review.
- Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.** Postma MJ, Heijnen ML, Beutels P, Jager JC. *Expert Rev Vaccines.* 2003 Aug;2(4):477-82.
- Costi ed effetti di Risperidone Long Acting (RLA) rispetto ad antipsicotici atipici nel trattamento dei soggetti schizofrenici in Itali.** Mantovani L, Berto P, D'Ausilio A, Heeg A. *Farmacoeconomia e percorsi terapeutici.* 01/2004; 5(1):5-11
- Pharmacoeconomic research.** Postma MJ. *Pharm World Sci.* 2003 Dec;25(6):245-6.
- Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States.** Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, Triulzi D, Staginnus U. *Clin Ther.* 2003 Sep;25(9):2464-86.
- A population based dynamic approach for estimating the cost effectiveness of screening for *Chlamydia trachomatis*.** Welte R, Kretzschmar M, van den Hoek JA, Postma MJ. *Sex Transm Infect.* 2003 Oct;79(5):426. No abstract available.
- Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes.** Postma MJ, Kruidhof H, de Jong-van den Berg LT, de Zeeuw D. *Expert Opin Pharmacother.* 2003 Sep;4(9):1543-50. Review. Erratum in: *Expert Opin Pharmacother.* 2003 Oct;4(10):1887.
- A pharmaco-economic comparison of the efficacy and costs of pantoprazole and omeprazole for the treatment of peptic ulcer or gastroesophageal reflux disease in The Netherlands.** van Hout BA, Klok RM, Brouwers JR, Postma MJ. *Clin Ther.* 2003 Feb;25(2):635-46.
- The economic profile of antenatal HIV testing: pharmaceutical and methodological considerations.** Postma MJ, Beck EJ, Sprenger HG, de Jong-van den Berg LT. *AIDS.* 2003 Mar 28;17(5):755-7. No abstract available.

**Cost-effectiveness of leucocyte depletion of red-cell transfusions for patients undergoing cardiac surgery.** Postma MJ, van de Watering LM, de Vries R, Versmoren D, van Hulst M, Tobi H, van der Poel CL, Brand A. *Vox Sang.* 2003 Jan;84(1):65-7. No abstract available.

**Cost-effectiveness of widespread screening for Chlamydia trachomatis.** Postma MJ, Welte R, Morré SA. *Expert Opin Pharmacother.* 2002 Oct;3(10):1443-50. Review.

**Costs and effects of risperdal constatm in comparison to conventional depot and short-acting atypical formulations in Germany.** Heeg B, Emmermann A, Laux G, Möller HJ, Naber D, van Hout B. *PMH10. Value in Health* 01/2003; 6(6):691-692.

**The use of modeling in the economic evaluation of vaccines.** Bos JM, Alphen Lv, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res.* 2002 Oct;2(5):443-55. doi: 10.1586/14737167.2.5.443.

**Pharmaco-economics of blood transfusion safety: review of the available evidence.** van Hulst M, de Wolf JT, Staginnus U, Ruitenber EJ, Postma MJ. *Vox Sang.* 2002 Aug;83(2):146-55. Review.

**[Pharmaco-economic aspects of vaccination against invasive pneumococcal infections in persons over 65 years of age; review of the literature on cost effectiveness analysis].** Postma MJ, Heijnen ML, Beutels P, Jager JC. *Ned Tijdschr Geneesk.* 2002 May 4;146(18):855-9. Dutch.

**The application of cost effectiveness analysis to derive a formulary for urinary tract infections.** Tramarin A, Bragagnolo L, Tolley K, Sartorelli S, Tositti G, Lazzarini L, Scagnelli M, Gallo R, Postma MJ, de Lalla F. *J Chemother.* 2002 Apr;14(2):166-74.

**Routine HIV screening of sexually transmitted disease clinic attenders has favourable cost-effectiveness ratio in low HIV prevalence settings.** Bos JM, van der Meijden WI, Swart W, Postma MJ. *AIDS.* 2002 May 24;16(8):1185-7.

**HIV post-exposure prophylaxis: enhancing its pharmaco-economic profile by discriminate prescribing.** Postma MJ, Bos JM, de Jong-van den Berg LT, Tramarin A, van Bergen JE. *AIDS.* 2002 May 24;16(8):1177-9. No abstract available.

**Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence.** Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT. *Drugs.* 2002;62(7):1013-24. Review.

**Cost-effectiveness of periconceptual supplementation of folic acid.** Postma MJ, Londeman J, Veenstra M, de Walle HE, de Jong-van den Berg LT. *Pharm World Sci.* 2002 Feb;24(1):8-11.

**Continued utilization and costs of proton pump inhibitors after Helicobacter pylori eradication in chronic users of gastrointestinal drugs.** Klok RM, Brouwers JR, Van den Berg PB, De Jong-Van den Berg LT, Tolley K, Postma MJ. *Aliment Pharmacol Ther.* 2002 May;16(5):1033-4. No abstract available.

**Cost-benefit analysis of the detection of prescribing errors by hospital pharmacy staff.** van den Bemt PM, Postma MJ, van Roon EN, Chow MC, Fijn R, Brouwers JR. *Drug Saf.* 2002;25(2):135-43.

**Major improvements in cost effectiveness of screening women for Chlamydia trachomatis using pooled urine specimens and high performance testing.** Morré SA, Welte R, Postma MJ. *Sex Transm Infect.* 2002 Feb;78(1):74-5. No abstract available.

**Comparing cost effectiveness of screening women for Chlamydia trachomatis in systematic and opportunistic approaches.** Postma MJ, Welte R, van den Hoek JA, Morré SA. *Sex Transm Infect.* 2002 Feb;78(1):73-4. No abstract available.

**Cost-effectiveness of screening for genital Chlamydia trachomatis.** Welte R, Jager H, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res.* 2001 Dec;1(2):145-56. doi: 10.1586/14737167.1.2.145.

**Cost-effectiveness of partner pharmacotherapy in screening women for asymptomatic infection with Chlamydia Trachomatis.** Postma MJ, Welte R, van den Hoek JA, van Doornum GJ, Jager HC, Coutinho RA. *Value Health.* 2001 May-Jun;4(3):266-75.

**A discrete events model of long-term outcomes and cost of treatment with long acting risperidone in schizophrenia.** Heeg B, van Aalst G, van den Arend I, Mehnert A, van Hout B. *PMH5. Value in Health* 11/2002; 5(6):515-516.

**Simulating the course of schizophrenia using discrete events modelling.** Heeg B, van Aalst G, Mehnert A, van Hout B. *PMH26. Value in Health* 01/2002; 5(6):524-524.

**The economics of HIV vaccines: projecting the impact of HIV vaccination of infants in sub-Saharan Africa.** Bos JM, Postma MJ. *Pharmacoeconomics*. 2001;19(9):937-46. Review.

**Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam.** Bos JM, Fennema JS, Postma MJ. *AIDS*. 2001 Oct 19;15(15):2031-6.

**Pharmacoeconomic evaluation of intensified antiretroviral treatment strategies in HIV/AIDS.** Bos JM, Berg LT, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2001 Oct;1(1):77-84. doi: 10.1586/14737167.1.1.77.

**Economic evaluations of adult pneumococcal vaccination strategies.** Beutels P, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2001 Oct;1(1):47-58. doi: 10.1586/14737167.1.1.47.

**Pharmacoeconomics of Helicobacter pylori: eradication versus maintenance therapy in controlling peptic ulcer disease.** Klok RM, Brouwers JR, Postma MJ. *Expert Rev Pharmacoecon Outcomes Res*. 2001 Oct;1(1):19-24. doi: 10.1586/14737167.1.1.19.

Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: potential impact of introduction in the Dutch vaccination program. Bos JM, Rümke HC, Welte R, Postma MJ, Jager JC. *Vaccine*. 2001 Oct 12;20(1-2):202-7.

**Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens.** van Valkengoed IG, Postma MJ, Morré SA, van den Brule AJ, Meijer CJ, Bouter LM, Boeke AJ. *Sex Transm Infect*. 2001 Aug;77(4):276-82.

**Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands.** Postma MJ, Heijnen ML, Jager JC. *Pharmacoeconomics*. 2001;19(2):215-22.

**Socio-economic aspects of extended STD screening in pregnancy.** Postma MJ, Jager JC, de Jong-van den Berg LT. *AIDS Care*. 2000 Dec;12(6):731-5.

**Comparative model-based analysis of screening programs for Chlamydia trachomatis infections.** Kretzschmar M, Welte R, van den Hoek A, Postma MJ. *Am J Epidemiol*. 2001 Jan 1;153(1):90-101.

**[Screening for asymptomatic Chlamydia trachomatis Infection in pregnancy; cost-effectiveness favorable at a minimum prevalence rate of 3% or more].** Postma MJ, Bakker A, Welte R, van Bergen JE, van den Hoek JA, de Jong-van den Berg LT, Jager JC. *Ned Tijdschr Geneeskd*. 2000 Dec 2;144(49):2350-4. Dutch.

**Cost effectiveness of expanded antenatal HIV testing in London.** Postma MJ, Beck EJ, Hankins CA, Mandalia S, Jager JC, de Jong-van den Berg LT, Walters MD, Sherr L. *AIDS*. 2000 Oct 20;14(15):2383-9.

**Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.** Postma MJ, Baltussen RM, Heijnen ML, de Berg LT, Jager JC. *Drugs Aging*. 2000 Sep;17(3):217-27. Review.

**Cost-effectiveness of screening programs for Chlamydia trachomatis: a population-based dynamic approach.** Welte R, Kretzschmar M, Leidl R, van den Hoek A, Jager JC, Postma MJ. *Sex Transm Dis*. 2000 Oct;27(9):518-29.

**[Pharmaco-economic evaluation of mandatory HIV-screening in pregnancy; a cost-efficacy analysis in Amsterdam].** Postma MJ, van den Hoek JA, Beck EJ, Heeg B, Jager JC, Coutinho RA. *Ned Tijdschr Geneeskd*. 2000 Apr 15;144(16):749-54. Dutch.

**Economic evaluation of influenza vaccination. Assessment for The Netherlands.** Postma MJ, Bos JM, van Gennep M, Jager JC, Baltussen R, Sprenger MJ. *Pharmacoeconomics*. 1999;16 Suppl 1:33-40. Review.

**Universal HIV screening of pregnant women in England: cost effectiveness analysis.** Postma MJ, Beck EJ, Mandalia S, Sherr L, Walters MD, Houweling H, Jager JC. *BMJ*. 1999 Jun 19;318(7199):1656-60.

**[Opportunistic screening for genital infections with Chlamydia trachomatis in sexually active population of Amsterdam. II. Cost-effectiveness analysis of screening women].** Postma MJ, Welte R, van den Hoek JA, van Doornum GJ, Coutinho RA, Jager JC. *Ned Tijdschr Geneeskd*. 1999 Mar 27;143(13):677-81. Dutch.

**Disease-staging for modelling current and future health-care impact of disease: illustrations for diabetes mellitus and AIDS.** Postma MJ, Jager JC, Ruwaard D, van Loy NC, Leidl RM. *Health Policy*. 1998 Jan;43(1):45-54.

**[Cost-effectiveness of influenza vaccination The Netherlands].** Reinders A, Postma MJ, Govaert TM, Sprenger MJ. Ned Tijdschr Geneeskd. 1997 Jan 11;141(2):93-7. Dutch.